About Us
Dr. Jeffrey Shenfeld MD
Dr. Michael Heublum MD
Dr. Michael Heublum MD
Dr Shenfeld expertise is in early detection, intervention and care for patients with early signs of cognitive decline and all kinds of dementia. His prevention approach is addressing risk factor levels at an early stage and continuing throughout the life course. Dr Shenfeld offers latest developments in genetic testing, computerised cogn
Dr Shenfeld expertise is in early detection, intervention and care for patients with early signs of cognitive decline and all kinds of dementia. His prevention approach is addressing risk factor levels at an early stage and continuing throughout the life course. Dr Shenfeld offers latest developments in genetic testing, computerised cognitive testing of short term memory and executive functions and exclusive imaging techniquest of volumetrics MRI and Amyloid PET Scans.
In addition to English, Dr. Shenfeld is fluent in Hebrew, Russian, Ukrainian, Polish and Korean expanding his accessibility to patients from diverse cultural backgrounds.
Dr. Jeffrey Shenfeld, MD, offers exceptional care as an experienced internist, focusing on comprehensive internal medicine. Dedicated to patient-centered care, Dr. Shenfeld specializes in diagnosing and managing a wide range of adult health conditions. His expertise ensures personalized treatment plans tailored to each patient's unique needs.
Dr. Michael Heublum MD
Dr. Michael Heublum MD
Dr. Michael Heublum MD
Dr. Michael Heublum is a skilled and qualified neurologist serving the community of New Jersey and New York. Dr. Heublum obtained his medical degree from the State University of New York Downstate Medical Center College of Medicine. He also completed his residency in internal medicine at Staten Island Hospital and residency in neurology
Dr. Michael Heublum is a skilled and qualified neurologist serving the community of New Jersey and New York. Dr. Heublum obtained his medical degree from the State University of New York Downstate Medical Center College of Medicine. He also completed his residency in internal medicine at Staten Island Hospital and residency in neurology at Mount Sinai Hospital. He then went on to complete a fellowship in neuromuscular diseases at the University of Michigan. He is board certified in neurology by the American Board of Psychiatry and Neurology. He is also certified by the American Board of Internal Medicine.
He is affiliated with the Mount Sinai Hospital in New York.
Dr. Heublum is uncompromising in his dedication to the well-being of his patients. He is committed to giving the best care and establishing long-lasting relationships with them. He exhibits his passion in the care and precision he takes with his patients.
QEEG
Our state-of-the-art system is the cutting-edge hardware and software that allows for objective cognitive functional assessment. QEEG is designed to aid physicians in diagnosis by effectively measuring biomarkers related to seizures, to memory loss, concussion, cognitive impairment, and other stress-related neurological conditions.
QEEG captures the electroencephalogram activity of the brain (EEG), electrocardiogram activity of the heart (ECG), visual and auditory processing speeds (evoked potentials), and a subjective neuropsychological survey. In addition, the system provides a comprehensive neuro-functional physiology report of the results, data summary, raw data, and images.
The QEEG system enables physicians to obtain specific neurophysiological biomarkers, which profile the patient's neurological function. Biomarkers allow the treating physician to gain additional clinical information vital to making a well-informed patient-care decision.
MMSE/MOCA/FAQ Tests
The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are cognitive tests used to assess mental function in dementia. The MMSE focuses on basic cognitive skills and has a maximum score of 30, with lower scores indicating impairment. MoCA is more comprehensive, assessing areas like attention, memory, language, and orientation; a score below 26 usually suggests cognitive deficits.
The Functional Activities Questionnaire (FAQ) differs by evaluating an individual's ability to perform daily activities, as reported by a caregiver. It assesses competencies in tasks like managing finances and shopping, with higher scores indicating greater functional impairment. This helps in understanding the practical impact of cognitive decline in daily life.
Cognivue
Cognivue is a powerful tool for diagnosing MCI and early dementia. With its advanced technology and specialized tests, Cognivue assesses various cognitive domains such as memory, attention, and executive function.
By establishing a baseline cognitive profile and tracking changes over time, it helps healthcare professionals detect subtle signs of cognitive decline. The standardized and automated testing reduces bias and ensures consistent and objective results. Cognivue's user-friendly interface also makes it accessible for patients, enhancing the diagnostic process for everyone involved.
Genetic Testing
Genetic testing can be a valuable tool in diagnosing Alzheimer's disease, especially in cases with a family history of the condition. Alzheimer's disease can have a genetic component, particularly in early-onset cases. Testing typically focuses on identifying mutations in specific genes known to be associated with the disease. The most commonly examined genes are APP, PSEN1, and PSEN2, mutations in which are linked to early-onset Alzheimer's. For late-onset Alzheimer's, the APOE gene is often analyzed, particularly the APOE ε4 allele, which increases the risk of developing the disease but is not determinative.
It's important to note that genetic testing for Alzheimer's is complex. While certain gene mutations can increase the risk, they do not guarantee the development of the disease. Conversely, one can develop Alzheimer's without these genetic markers. Therefore, genetic testing is usually complemented by a comprehensive assessment that includes medical history, neurological exams, and cognitive testing. Genetic counseling is also recommended to help individuals understand the implications of the test results for themselves and their family members.
TCD/Carotid Ultrasound
TCD and carotid imaging techniques are valuable tools in diagnosing dementia. TCD measures blood flow velocity in cerebral arteries, detecting abnormalities that contribute to cognitive decline. Carotid imaging examines carotid arteries, identifying blockages or narrowing that impede blood flow to the brain.
These techniques complement cognitive assessments, aiding in differential diagnosis and guiding treatment strategies. They also monitor interventions targeting vascular health, potentially slowing dementia progression. Overall, TCD and carotid imaging provide crucial insights into the vascular factors associated with dementia.
Sleep Disorder Test
Electroencephalography (EEG) and home sleep testing kits are valuable tools in diagnosing sleep disorders that can have a profound impact on cognitive health. Research has shown that sleep disturbances can contribute to memory loss and increase the risk of developing Alzheimer's disease. By analyzing brain wave activity during sleep, EEG can detect abnormalities in sleep patterns that may be linked to cognitive decline. Home sleep testing kits provide additional insights into sleep quality, duration, and stages, helping to identify potential sleep-related contributors to memory impairment.
By identifying and addressing underlying sleep disorders, individuals can take proactive steps to mitigate the risk of memory loss and Alzheimer's disease. Early detection and treatment of sleep disorders, such as sleep apnea and insomnia, can help preserve cognitive function and reduce the likelihood of dementia. Our sleep disorder test is a crucial step in uncovering the link between sleep and cognitive health, empowering individuals to take control of their brain health.
TMS
Transcranial Magnetic Stimulation (TMS) holds potential in aiding the management of dementia. TMS has been investigated as a therapeutic tool to enhance cognitive function in individuals with dementia. Studies have shown that repetitive TMS (rTMS) targeted at specific brain regions can improve cognitive performance, including memory and executive function, in patients with Alzheimer's disease and other types of dementia. By modulating neuronal activity and promoting neuroplasticity, TMS may help counteract cognitive decline and potentially slow the progression of dementia.
MRI/PET Scans
MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans are advanced imaging techniques that play a crucial role in diagnosing Alzheimer's disease.
MRI scans are used to produce detailed images of the brain's structure. They can detect changes in brain size and volume, which are indicative of Alzheimer's. In Alzheimer's patients, MRI can reveal shrinkage in specific areas of the brain responsible for memory and cognitive functions, such as the hippocampus and temporal lobes. This atrophy is a key sign of Alzheimer's and other forms of dementia.
PET scans, on the other hand, are used to analyze the brain's metabolic activity. A specific type of PET scan, known as amyloid imaging, can detect the presence of amyloid plaques, a hallmark of Alzheimer's disease. These plaques, made up of protein fragments, accumulate in the brains of Alzheimer's patients and disrupt cell function. Another type of PET scan can measure glucose metabolism in the brain, as Alzheimer’s affects the brain's ability to use glucose in its energy metabolism.
Together, MRI and PET scans provide complementary information. While MRI shows structural changes in the brain, PET reveals the biochemical changes. When combined with clinical assessments and other tests, these imaging techniques contribute significantly to the accurate diagnosis and understanding of Alzheimer's disease progression
Blood Tests
Recent advancements in medical research have led to the development of blood tests that can aid in the diagnosis of Alzheimer's disease. These blood tests primarily focus on detecting specific biomarkers associated with the condition.
One of the key biomarkers is the abnormal levels of beta-amyloid, a protein fragment that accumulates in the brains of Alzheimer's patients, forming plaques. Blood tests can measure the ratios of different forms of amyloid beta, such as amyloid beta 42 to amyloid beta 40. An abnormal ratio is suggestive of Alzheimer's disease.
Another biomarker is the tau protein, which forms tangles inside neurons in Alzheimer's patients. Specific forms of phosphorylated tau (p-tau) are found at higher levels in the blood of individuals with Alzheimer's.
These blood tests offer a less invasive and more accessible diagnostic option compared to brain scans and cerebrospinal fluid analysis. While they are a significant step forward, it's important to note that these tests are typically used in conjunction with other diagnostic methods, such as cognitive assessments and imaging scans, to confirm a diagnosis of Alzheimer's disease. This integrated approach helps ensure a more accurate and comprehensive diagnosis.
